Moderna to conduct trials for its new mRNA products in Taiwan

Moderna sees Taiwan as a crucial site for clinical trials necessary for refining its mRNA technology, and will include it as a site for its multicenter trials, said Patrick Bergstedt, a senior vice president of Moderna, on Tuesday during his first visit to the country.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)